NexBio, Inc./10665 Sorrento Valley Rd, San Diego, CA 92121, USA.
Viruses. 2010 Aug;2(8):1766-1781. doi: 10.3390/v2081766. Epub 2010 Aug 20.
While vaccines are the primary public health response to seasonal and pandemic flu, short of a universal vaccine there are inherent limitations to this approach. Antiviral drugs provide valuable alternative options for treatment and prophylaxis of influenza. Here, we will review drugs and drug candidates against influenza with an emphasis on the recent progress of a host-targeting entry-blocker drug candidate, DAS181, a sialidase fusion protein.
虽然疫苗是季节性和大流行性流感的主要公共卫生应对措施,但在缺乏通用疫苗的情况下,这种方法存在固有局限性。抗病毒药物为流感的治疗和预防提供了有价值的替代选择。在这里,我们将回顾针对流感的药物和药物候选物,重点介绍最近进展迅速的一种宿主靶向进入抑制剂药物候选物 DAS181,即一种唾液酸酶融合蛋白。